New York-based agribusiness asset manager Amerra Capital Management acquired more than 90 percent of Norway-based fish byproduct protein producer Marine Bioproducts/Biomega, it was announced Thursday.
At the same time, Amerra is acquiring 100 percent of Alkymar, a Norwegian provider of industrial enzymatic hydrolysis solutions, that works in the marine industry.
Biomega's purpose is to conserve the nutritional value of byproducts from the salmon farming industry.
While those byproducts are generally destined for lower-grade animal feed, Biomega developed technology applications for premium food and human nutrition market segments.
